From a technology‑centric perspective, the blood group typing market is divided into four principal type categories. Serological methods—including tube, gel, and column agglutination—remain the baseline for high‑throughput hospital laboratories, accounting for roughly 40 % of unit shipments due to their low cost and established protocols. Molecular methods—such as PCR‑SSP, real‑time PCR, and next‑generation sequencing—capture about 30 % of revenue, driven by the need for genotype‑level resolution in transplant compatibility and rare‑phenotype detection. Automated platforms integrate robotic sample handling with optical read‑out, contributing an estimated 20 % of market value as hospitals seek workflow efficiency and reduced human error. Finally, point‑of‑care devices—compact cartridge‑based systems designed for bedside or field use—represent the remaining 10 %, reflecting growing demand in emergency, military, and low‑resource settings. Each type segment adds distinct cost structures, throughput capacities, and regulatory pathways, collectively shaping the overall market taxonomy for blood group typing technology. Adoption rates are influenced by reimbursement policies and the pace of integration, with automated and point‑of‑care solutions expected to accelerate as medical records become ubiquitous. Cost‑benefit analyses increasingly favor molecular assays in centers, while serological kits dominate volume‑driven markets.
